Pelizaeus-Merzbacher spectrum disorder is caused by pathogenic variants in PLP1, located on chromosome X, as documented in the packet's known_genes and gene_locations fields. The PLP1–disease association is classified as DEFINITIVE by ClinGen, per the packet's known_genes_with_validity field. The packet's inheritance_patterns field records X-linked inheritance, consistent with GeneReviews documentation. GeneReviews describes several variant classes with distinct phenotypic associations. PLP1 duplications are the most common cause and predominantly produce the classic PMD phenotype; copy number variation in duplication extent or breakpoint location may account for clinical variability. Missense variants, particularly nonconservative amino acid substitutions, are associated with the most severe phenotypes. Conservative amino acid substitutions in less critical protein regions are typically associated with SPG2. Null PLP1 variants — including deletions, frameshift variants, and missense variants affecting the start codon — produce a relatively milder phenotype with peripheral neuropathy (PLP1 null syndrome). GeneReviews notes that pathogenic variants in the PLP1-specific domain encoded by amino acid residues 117–151 and in intron 3 tend to cause less severe phenotypes. A minority of affected males carry de novo pathogenic variants; in most families the mother is a heterozygous carrier.

GeneReviews notes that no consensus diagnostic criteria for PLP1-related disorders have been published. Diagnosis in a male proband is established by identification of a hemizygous pathogenic or likely pathogenic variant in PLP1 through molecular genetic testing. In female probands, diagnosis typically requires neurologic signs, a family history consistent with PLP1-related disorder, and identification of a heterozygous PLP1 pathogenic variant. Suggestive clinical findings described in GeneReviews include infantile or early childhood onset of nystagmus with hypotonia and cognitive impairment, progressive spasticity and ataxia, spastic paraparesis, and spastic urinary bladder. Brain MRI is a key diagnostic investigation: T2-weighted or FLAIR imaging characteristically shows diffusely increased T2 signal in the white matter of the cerebral hemispheres, cerebellum, and brainstem, consistent with hypomyelination. GeneReviews notes that absence of expected early myelination landmarks on MRI — including signal changes in the pons, cerebellum, posterior limb of the internal capsule, splenium of the corpus callosum, and optic radiations — in a young infant prompts consideration of PMD. Magnetic resonance spectroscopy may show reduced white matter N-acetyl aspartate levels. Family history consistent with X-linked inheritance (no male-to-male transmission) supports the diagnosis.

No FDA-approved treatments are listed in the packet's approved_treatments or foundational_therapies fields for Pelizaeus-Merzbacher spectrum disorder. One agent holds an FDA orphan drug designation (not approval) for Pelizaeus-Merzbacher disease: a 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA, sponsored by Ionis Pharmaceuticals, Inc. GeneReviews describes a supportive care framework in the absence of published clinical practice guidelines. Areas addressed include respiratory status assessment; feeding management including gastrostomy tube placement for persistent dysphagia; spasticity management through physical and occupational therapy, orthopedic surgery for severe contractures, and pharmacologic agents noted in GeneReviews including baclofen (including intrathecal administration), diazepam, and tizanidine; and seizure management with anti-seizure medications in individuals with the most severe connatal phenotype. GeneReviews notes that elevated body temperature, as with fever, may cause neurologic manifestations to transiently worsen.

GeneReviews provides phenotype-specific life expectancy and functional outcome data. In severe connatal PMD, affected individuals do not achieve ambulation and verbal expression is severely limited; lifespan ranges from infancy to the third decade with attentive care. Classic PMD individuals may live into the third to seventh decade; ambulation if acquired is typically lost in childhood or adolescence. PLP1 null syndrome individuals retain ambulation and have a lifespan estimated in the fifth to seventh decade. Complicated SPG2 with HEMS individuals generally retain ambulation with lifespan in the fourth to seventh decade. Uncomplicated SPG2 individuals may have normal lifespan with retained ambulation and preserved cognition. GeneReviews also notes that low bone density may develop as mobility is reduced. The packet's natural_history field contains no data beyond GeneReviews content.

Five active clinical trials are documented in the packet. NCT05659901 (Rocket Study: Biomarkers and Disease Progression in Pelizaeus-Merzbacher Disease, recruiting, Ionis Pharmaceuticals, through March 2029). NCT06150716 (Orbit Study: Safety, pharmacokinetics, and pharmacodynamics of intrathecally administered ION356 in Pelizaeus-Merzbacher Disease, Phase 1, recruiting, Ionis Pharmaceuticals, through June 2028). NCT02254863 (UCB Transplant of Inherited Metabolic Diseases with Intrathecal Oligodendrocyte-Like Cells, Phase 1, recruiting, Joanne Kurtzberg/Duke, through October 2026). NCT03047369 (Myelin Disorders Biorepository Project, recruiting, Children's Hospital of Philadelphia, through December 2030). NCT03333200 (Longitudinal Study of Neurodegenerative Disorders, recruiting, University of Pittsburgh, through January 2035). GeneReviews also describes prior and ongoing investigational approaches: CNS stem cell transplantation was evaluated in an FDA-approved Phase 1 trial with minimal evidence of myelination; antisense oligonucleotide gene therapy targeting PLP1 expression is currently in clinical trial evaluation and was effective in disease models; deferiprone (an iron chelator) is currently in clinical trial evaluation and has shown phenotype improvement in cell and animal models. Curcumin showed promise in cell models but was not effective in a small clinical group.